Clinical Trial Update: Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 [Phase 3]

View source ↗

Summary

Phase 3 fixed-dose pediatric trial (ages 6-17) evaluating CTx-1301 for ADHD has completed with efficacy and safety results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CTx-1301

Snippet

Sponsor: Cingulate Therapeutics | Conditions: ADHD, Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2026-01-22